Jeitler, K. and Semlitsch, T. (2012): Bevacizumab (Avastin®) in combination with chemotherapy in previously treated metastatic breast cancer. DSD: Horizon Scanning in Oncology 27.
Semlitsch, T. and Zengerer, A. and Jeitler, K. (2013): Dabrafenib (Tafinlar®) in previously untreated subjects with BRAF mutation-positive advanced (stage III) or metastatic (stage IV) melanoma. DSD: Horizon Scanning in Oncology 42.
Jeitler, K. and Semlitsch , T. (2012): Everolimus (Afinitor® or Votubia®) in combination with exemestane in postmenopausal women with oestrogen receptor positive, HER2-negative locally advanced or metastatic breast cancer who are refractory to letrozole or anastrozole. DSD: Horizon Scanning in Oncology 32.
Semlitsch , T. and Jeitler, K. (2013): Crizotinib (Xalkori®) for the treatment of anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) . DSD: Horizon Scanning in Oncology 35.
Semlitsch, T. and Zengerer, A. and Jeitler, K. (2014): Nab-Paclitaxel (Abraxane®) as first-line therapy for metastatic adenocarcinoma of the pancreas. DSD: Horizon Scanning in Oncology 43.